Travere Therapeutics, Inc. (NASDAQ:TVTX) Cantor International Healthcare Convention 2025 September 4, 2025 2:45 PM EDT
Firm Individuals
Eric Dube – President, CEO & Director
Peter Heerma – Chief Business Officer
Convention Name Individuals
Prakhar Agrawal – Cantor Fitzgerald & Co., Analysis Division
Presentation
Prakhar Agrawal
Senior Biotech Analyst
All proper. Hi there, everybody. My title is Prakhar Agrawal. I am a biotech analyst at Cantor. Welcome to day 2 of the Cantor’s International Healthcare Convention. For the following session, we’re very excited to host the group of Travere Therapeutics. Representing Travere, we now have Eric Dube, President and CEO; and Peter Heerma, Chief Business Officer. Gents, thanks for coming.
Eric Dube
President, CEO & Director
Thanks for internet hosting us.
Peter Heerma
Chief Business Officer
My pleasure.
Query-and-Reply Session
Prakhar Agrawal
Cantor Fitzgerald & Co., Analysis Division
So clearly, lots happening at Travere proper now. We’ll go into the specifics. However possibly simply to stage set expectations, why do not you begin with an summary of the important thing priorities proper now for the corporate?
Eric Dube
President, CEO & Director
Certain. So that is certainly an thrilling yr for Travere and the function that we glance to play throughout the uncommon kidney and broader uncommon illness house. Our #1 precedence for this yr is to proceed the success of the launch of FILSPARI in IgA nephropathy. And we have been more than happy with the efficiency for the primary half of the yr. And we have some very thrilling updates to proceed that success within the again half of this yr, together with the latest modification of the liver monitoring REMS and the elimination of the being pregnant testing REMS, which makes it that a lot easier for sufferers to entry.
The second precedence is the continued work with FDA for the potential approval in FSGS. This might be
